Last reviewed · How we verify
Tocilizumab Prefilled Syringe [Actemra]
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.
Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.
At a glance
| Generic name | Tocilizumab Prefilled Syringe [Actemra] |
|---|---|
| Also known as | Actemra |
| Sponsor | Medical University of Vienna |
| Drug class | IL-6 receptor antagonist |
| Target | IL-6R |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism of action is particularly useful in treating autoimmune diseases and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Juvenile idiopathic arthritis
- Giant cell arteritis
- Polyarticular juvenile idiopathic arthritis
- Systemic sclerosis
- Cryopyrin-associated periodic syndromes
- Carvajal syndrome
- Eosinophilic granulomatosis with polyangiitis
- COVID-19
Common side effects
- Increased risk of infections
- Neutropenia
- Anemia
- Thrombocytopenia
- Hypersensitivity reactions
- Increased risk of malignancies
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: